OncoAlert and ecancer - ESMO 2021 Day 3

Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer

KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resected stage II melanoma

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer

OncoAlert and ecancer - ESMO 2021 Day 2

ESMO President: What to watch for at ESMO 2021

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma

Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy

Idecabtagene vicleucel for relapsed and refractory multiple myeloma

OncoAlert and ecancer weekly round up for August 2 - August 14, 2021